Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Health Maintenance Organizations | 8 | 2007 | 682 | 0.410 |
Why?
|
| Treatment Refusal | 5 | 2008 | 435 | 0.280 |
Why?
|
| Patient Compliance | 7 | 2009 | 2763 | 0.260 |
Why?
|
| Confidence Intervals | 1 | 2008 | 3057 | 0.240 |
Why?
|
| Drug Utilization | 7 | 2008 | 1248 | 0.240 |
Why?
|
| Benzodiazepines | 5 | 2007 | 1040 | 0.200 |
Why?
|
| RNA Polymerase II | 1 | 2003 | 526 | 0.190 |
Why?
|
| Blood Glucose Self-Monitoring | 3 | 2007 | 286 | 0.180 |
Why?
|
| Drug Therapy | 3 | 2008 | 531 | 0.180 |
Why?
|
| Drug Prescriptions | 5 | 2008 | 1683 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2008 | 5104 | 0.160 |
Why?
|
| Research Design | 3 | 2008 | 5835 | 0.160 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2003 | 883 | 0.150 |
Why?
|
| Drug Costs | 4 | 2008 | 1125 | 0.140 |
Why?
|
| Medicare Part D | 2 | 2008 | 281 | 0.140 |
Why?
|
| Legislation, Drug | 2 | 2007 | 224 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 2 | 2007 | 398 | 0.130 |
Why?
|
| Prescriptions | 2 | 2008 | 282 | 0.130 |
Why?
|
| Medical Indigency | 3 | 2008 | 65 | 0.130 |
Why?
|
| Antidepressive Agents | 4 | 2007 | 2764 | 0.130 |
Why?
|
| Postnatal Care | 3 | 2004 | 220 | 0.130 |
Why?
|
| Health Policy | 5 | 2008 | 2596 | 0.120 |
Why?
|
| Diabetes Mellitus | 6 | 2009 | 4958 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 6009 | 0.110 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2007 | 344 | 0.100 |
Why?
|
| Hypoglycemic Agents | 5 | 2009 | 2592 | 0.100 |
Why?
|
| Medicaid | 6 | 2008 | 2479 | 0.100 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 98 | 0.090 |
Why?
|
| Hip Fractures | 2 | 2007 | 862 | 0.090 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 117 | 0.090 |
Why?
|
| Sampling Studies | 1 | 2008 | 653 | 0.080 |
Why?
|
| Marketing | 1 | 2008 | 230 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2008 | 6669 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 178 | 0.070 |
Why?
|
| Length of Stay | 3 | 2004 | 6241 | 0.070 |
Why?
|
| Depressive Disorder | 3 | 2007 | 3893 | 0.070 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 64 | 0.070 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 472 | 0.070 |
Why?
|
| Pirenzepine | 1 | 2003 | 118 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 354 | 0.060 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2003 | 45 | 0.060 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2003 | 45 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2003 | 77 | 0.060 |
Why?
|
| Antipsychotic Agents | 2 | 2008 | 3015 | 0.060 |
Why?
|
| Patient Discharge | 3 | 2003 | 2754 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2006 | 514 | 0.060 |
Why?
|
| Medicare | 3 | 2008 | 5077 | 0.060 |
Why?
|
| Ribonucleases | 1 | 2003 | 282 | 0.060 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 262 | 0.060 |
Why?
|
| Haloperidol | 1 | 2003 | 389 | 0.060 |
Why?
|
| Histidine | 1 | 2003 | 340 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1261 | 0.060 |
Why?
|
| Fee-for-Service Plans | 1 | 2006 | 636 | 0.060 |
Why?
|
| Disabled Persons | 2 | 2007 | 1097 | 0.060 |
Why?
|
| Infant Care | 1 | 2002 | 204 | 0.050 |
Why?
|
| COS Cells | 1 | 2003 | 1261 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2008 | 10088 | 0.050 |
Why?
|
| Alanine | 1 | 2003 | 608 | 0.050 |
Why?
|
| Warfarin | 1 | 2008 | 1433 | 0.050 |
Why?
|
| Massachusetts | 7 | 2007 | 8920 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2008 | 12734 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2003 | 697 | 0.050 |
Why?
|
| New York | 3 | 2007 | 856 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 848 | 0.050 |
Why?
|
| Aftercare | 1 | 2003 | 537 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2004 | 836 | 0.040 |
Why?
|
| Breast Feeding | 2 | 2004 | 1376 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2004 | 995 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2003 | 1147 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2006 | 2410 | 0.040 |
Why?
|
| Plasmids | 1 | 2003 | 2518 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1889 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2003 | 3395 | 0.040 |
Why?
|
| New Jersey | 2 | 2007 | 271 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 2371 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 4184 | 0.040 |
Why?
|
| Humans | 33 | 2009 | 686663 | 0.040 |
Why?
|
| Health Expenditures | 2 | 2008 | 2154 | 0.030 |
Why?
|
| Disease Management | 1 | 2006 | 2586 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2003 | 5678 | 0.030 |
Why?
|
| Transfection | 1 | 2003 | 6329 | 0.030 |
Why?
|
| Male | 24 | 2009 | 352465 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 1433 | 0.030 |
Why?
|
| Aged | 16 | 2009 | 162271 | 0.030 |
Why?
|
| Female | 25 | 2009 | 375459 | 0.030 |
Why?
|
| Health Care Surveys | 3 | 2007 | 2527 | 0.030 |
Why?
|
| Binding Sites | 1 | 2003 | 6499 | 0.030 |
Why?
|
| Middle Aged | 18 | 2009 | 216468 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2008 | 4173 | 0.030 |
Why?
|
| Socioeconomic Factors | 4 | 2008 | 7933 | 0.030 |
Why?
|
| State Health Plans | 2 | 2006 | 218 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2004 | 1795 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2003 | 3602 | 0.030 |
Why?
|
| Anxiety | 1 | 2006 | 3597 | 0.030 |
Why?
|
| African Americans | 1 | 2007 | 5144 | 0.030 |
Why?
|
| Pain | 1 | 2006 | 4295 | 0.030 |
Why?
|
| Demography | 2 | 2006 | 1583 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2003 | 8896 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2006 | 3037 | 0.030 |
Why?
|
| United States | 9 | 2008 | 65579 | 0.030 |
Why?
|
| Longitudinal Studies | 4 | 2009 | 13444 | 0.030 |
Why?
|
| Adult | 15 | 2009 | 211400 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2009 | 3975 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2006 | 4303 | 0.030 |
Why?
|
| Peptides | 1 | 2003 | 4537 | 0.030 |
Why?
|
| Protein Binding | 1 | 2003 | 9947 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 6549 | 0.020 |
Why?
|
| Maine | 1 | 2008 | 135 | 0.020 |
Why?
|
| New Hampshire | 1 | 2008 | 189 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 8130 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 474 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cohort Studies | 5 | 2008 | 38732 | 0.020 |
Why?
|
| Diabetes Complications | 2 | 2006 | 1420 | 0.020 |
Why?
|
| Depressive Disorder, Major | 1 | 2004 | 4299 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2003 | 4998 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2006 | 102 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 117 | 0.020 |
Why?
|
| Oxycodone | 1 | 2006 | 119 | 0.020 |
Why?
|
| Financing, Personal | 1 | 2008 | 319 | 0.020 |
Why?
|
| Self Administration | 1 | 2006 | 398 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 5182 | 0.020 |
Why?
|
| Methadone | 1 | 2006 | 260 | 0.020 |
Why?
|
| Aged, 80 and over | 5 | 2008 | 59331 | 0.020 |
Why?
|
| Leucine Zippers | 1 | 2004 | 122 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2004 | 102 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 155 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 11910 | 0.020 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2006 | 257 | 0.020 |
Why?
|
| Half-Life | 1 | 2004 | 691 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 768 | 0.020 |
Why?
|
| Age Factors | 3 | 2007 | 19295 | 0.020 |
Why?
|
| Retrospective Studies | 5 | 2009 | 67320 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 365 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 634 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 11616 | 0.010 |
Why?
|
| Logistic Models | 2 | 2008 | 13807 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2007 | 951 | 0.010 |
Why?
|
| Phototherapy | 1 | 2004 | 338 | 0.010 |
Why?
|
| Personality Inventory | 1 | 2003 | 1065 | 0.010 |
Why?
|
| Comorbidity | 2 | 2007 | 10648 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2436 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 1858 | 0.010 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 365 | 0.010 |
Why?
|
| Prevalence | 2 | 2007 | 14744 | 0.010 |
Why?
|
| Cost Control | 1 | 2002 | 644 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 781 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 1254 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2004 | 23953 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 2004 | 909 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 1915 | 0.010 |
Why?
|
| Psychometrics | 1 | 2008 | 2954 | 0.010 |
Why?
|
| Milk, Human | 1 | 2003 | 498 | 0.010 |
Why?
|
| Data Collection | 1 | 2008 | 3321 | 0.010 |
Why?
|
| Mutation | 1 | 2003 | 28848 | 0.010 |
Why?
|
| Adolescent | 4 | 2008 | 84957 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2003 | 440 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 5114 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4119 | 0.010 |
Why?
|
| Home Care Services | 1 | 2002 | 556 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2006 | 2560 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4804 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 2228 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6786 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 1674 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2760 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2004 | 1294 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 21640 | 0.010 |
Why?
|
| Psychiatry | 1 | 2007 | 1502 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 170849 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 3621 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 3340 | 0.010 |
Why?
|
| Social Class | 1 | 2003 | 1982 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2003 | 1941 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 7202 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12525 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 4355 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 6389 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4115 | 0.010 |
Why?
|
| Insulin | 1 | 2007 | 6521 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2003 | 2693 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 39737 | 0.010 |
Why?
|
| Young Adult | 2 | 2008 | 56052 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3016 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 8882 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 2671 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 21684 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 9534 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2007 | 4407 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 15597 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 19308 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 4928 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 11866 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10990 | 0.010 |
Why?
|
| Health Status | 1 | 2003 | 4011 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 17251 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 12323 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2002 | 2917 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 20496 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 16091 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 23439 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18495 | 0.000 |
Why?
|
| Hospitalization | 1 | 2002 | 9304 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 7110 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 24351 | 0.000 |
Why?
|
| Child | 1 | 2008 | 71361 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 80803 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2003 | 60991 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 69278 | 0.000 |
Why?
|
| Neoplasms | 1 | 2003 | 19538 | 0.000 |
Why?
|
Concepts
(210)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_